
<DOC>
<DOCNO>WT03-B24-206</DOCNO>
<DOCOLDNO>IA064-000380-B023-255</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/library/fi/fi.htm 206.86.52.80 19970112102010 text/html 2889
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 10:20:12 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 2707
Last-modified: Thu, 08 Feb 1996 23:16:24 GMT
</DOCHDR>

<HTML>
<BODY background = "../../graphics/white-mi.gif">
<HEAD><TITLE>FINANCE & INVESTMENT</TITLE></HEAD>



<H1><CENTER>Finance & Investment</H1></CENTER>


<B><A HREF="../../archive/1995/3qtr/0807a1.htm">Biotech Bulls</A></B><BR>
This story describes the emergence of a long-awaited rally in biotechnology stocks. The rally is supported by increasing share prices based on fundamentals and macroeconomic events. But the relative absence of new investors, continued investor preference for mature companies, and sluggishness of initial public offerings indicate that the market will be selective. 7.8.95 (3000 words)<P>


<B><A HREF="../../archive/1995/1qtr/0227a1.htm">The Intersection of Art and Technology</A></B><BR>
This story discusses return on investment at it applies to technology service providers in the biotechnology sector. Interviews with executives from drug discovery and enabling technology companies provide a framework for valuation of genomics, combinatorial chemistry and drug screening companies. 27.2.95<P>


<B><A HREF="../../archive/1995/1qtr/0109b1.htm">Kleiner Perkins Breaks its Rules</A></B><BR>
This feature discusses a new business and financing model at Corixa Corp. applied by the venture capital firm Kleiner Perkins Caufield & Byers. With previous start-ups built almost solely around differentiating technology, the now uncertain financing environment for biotechnology has prompted the firm to put together a top management team and a significant financing package for Corixa, which is developing T cell vaccines. 9.1.95 (780 words)<P>


<B><A HREF="../../archive/1995/1qtr/0103a1.htm">Capitalist Road</A></B><BR>
This commentary analyzes 1994 market performance compared with industry fundamentals and looks ahead to 1995.  The BioCentury 100 Index was down 29% in 1994 on top of an 18% decline in 1993. Yet this performance may be "normal" for this stage of industry development.  Investment in 1995 will focus on companies with advanced products, cash and financial resources. 3.1.95 (2,350 words)<P>

<h5><HR>

<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0
<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/kanjipg.htm"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>

<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks of BioCentury Publications Inc. All other trade marks are the property of their respective owners. </H5><P>



</BODY></HTML>




</DOC>